Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
1) To compare the overall survival of previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum treated with MK3475 compared to docetaxel. 2) To compare progression free survival (PFS) per RECIST 1.1 by independent radiologists' review of previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum treated with MK3475 compared to docetaxel. 3) To evaluate OS of previously treated subjects with NSCLC whose tumors express PD-L1 and are treated with MK-3475 compared to docetaxel. 4) To evaluate PFS per RECIST 1.1 by independent radiologists’ review of previously treated subjects with NSCLC whose tumors express PD-L1 and are treated with MK-3475 compared to docetaxel. 5) Evaluate safety and tolerability profile of MK3475 in previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum.
Inclusion criteria
- Lung cancer